Literature DB >> 8940231

Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis.

J Campos1, F Román, M Georgiou, C García, R Gómez-Lus, R Cantón, H Escobar, F Baquero.   

Abstract

Ciprofloxacin has been a major advance in the treatment of chronic respiratory infections. Three patients with cystic fibrosis and colonized by 5 nontypeable Haemophilus influenzae strains exhibiting low- (MIC, 2 microg/mL) and high-level ciprofloxacin resistance (MICs, 16-32 microg/mL) are described. The patients had received several courses of ciprofloxacin. These MICs represent a decrease in ciprofloxacin susceptibility of 200-3200 times. Molecular epidemiologic methods demonstrated that 2 patients were chronically colonized by their own ciprofloxacin-resistant strains for > or = 15-17 months. Three strains showed simultaneous resistance to ampicillin and chloramphenicol by enzyme inactivation, and 2 had ampicillin resistance without beta-lactamase activity. These data suggest that the emergence and long-term persistence of ciprofloxacin-resistant H. influenzae in patients with cystic fibrosis can be a consequence of antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940231     DOI: 10.1093/infdis/174.6.1345

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.

Authors:  María Pérez-Vázquez; Federico Román; Silvia García-Cobos; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

2.  Melting curve analysis for rapid detection of topoisomerase gene mutations in Haemophilus influenzae.

Authors:  Shigeki Nakamura; Katsunori Yanagihara; Yoshitomo Morinaga; Koichi Izumikawa; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Shimeru Kamihira; Shigeru Kohno
Journal:  J Clin Microbiol       Date:  2009-01-07       Impact factor: 5.948

3.  Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin.

Authors:  J Vila; J Ruiz; F Sanchez; F Navarro; B Mirelis; M T de Anta; G Prats
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.

Authors:  Carmen Puig; José Manuel Tirado-Vélez; Laura Calatayud; Fe Tubau; Junkal Garmendia; Carmen Ardanuy; Sara Marti; Adela G de la Campa; Josefina Liñares
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

Review 5.  The emerging relationship between the airway microbiota and chronic respiratory disease: clinical implications.

Authors:  Yvonne J Huang; Susan V Lynch
Journal:  Expert Rev Respir Med       Date:  2011-12       Impact factor: 3.772

6.  Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV.

Authors:  Xinying Li; Noriel Mariano; James J Rahal; Carl M Urban; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains.

Authors:  Federico Román; Rafael Cantón; María Pérez-Vázquez; Fernando Baquero; José Campos
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

8.  Changes in the prevalence of resistant Escherichia coil in cattle receiving subcutaneously injectable oxytetracycline in addition to in-feed chlortetracycline compared with cattle receiving only in-feed chlortetracycline.

Authors:  A M O'Connor; C Poppe; S A McEwen
Journal:  Can J Vet Res       Date:  2002-07       Impact factor: 1.310

9.  Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.

Authors:  María Pérez-Vázquez; Federico Román; Belén Aracil; Rafael Cantón; José Campos
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

10.  In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.

Authors:  María Pérez-Vázquez; Federico Román; Belen Aracil; Rafael Cantón; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.